Farkona Sofia, Soosaipillai Antoninus, Filippou Panagiota, Liaskos Christos, Bogdanos Dimitrios P, Diamandis Eleftherios P, Blasutig Ivan M
.
Clin Chem Lab Med. 2017 Aug 28;55(10):1574-1581. doi: 10.1515/cclm-2016-1120.
Pancreatic autoantibodies (PABs) are detected in patients with inflammatory bowel disease (IBD). Their prevalence is higher in Crohn's disease (CrD) than in ulcerative colitis (UC). Glycoprotein 2 (GP2) and, more recently, CUB and zona pellucida-like domain-containing protein 1 (CUZD1) have been identified as target autoantigens of PAB. The clinical utility of CUZD1 autoantibodies has only recently been assessed by indirect immunofluorescence (IIF) assays. In this study, we developed and validated novel immunoassays for the detection of CUZD1 autoantibodies.
Recombinant CUZD1 protein was utilized as a solid-phase antigen for the development of two immunoassays for the detection of IgG and IgA CUZD1 autoantibodies. Serum samples from 100 patients with CrD, 100 patients with UC, 129 patients assessed for various autoimmune diseases (vADs) and 50 control individuals were analyzed.
Two immunofluorometric assays for the detection of IgG and IgA CUZD1-specific antibodies were developed. CUZD1 autoantibodies were detected in 12.5% (25/200) IBD patients, including 16% of patients with CrD and in 9% of patients with UC (CrD vs. UC, p<0.05), compared with 3.1% (4/129) patients suspected of having vADs (CrD vs. ADs, p<0.05; UC vs. ADs, p=0.08). CUZD1 autoantibody positivity was not found to be related to disease location, age of disease onset or disease phenotype.
This is the first study to describe novel IgA and IgG CUZD1 autoantibody enzyme-linked immunosorbent assay. These immunoassays agree well with standard IIF techniques and can be utilized in multicenter studies to investigate the diagnostic and clinical utility of CUZD1 autoantibodies.
在炎症性肠病（IBD）患者中可检测到胰腺自身抗体（PAB）。其在克罗恩病（CrD）中的患病率高于溃疡性结肠炎（UC）。糖蛋白2（GP2）以及最近发现的含CUB和透明带样结构域蛋白1（CUZD1）已被确定为PAB的靶自身抗原。CUZD1自身抗体的临床应用最近才通过间接免疫荧光（IIF）检测进行评估。在本研究中，我们开发并验证了用于检测CUZD1自身抗体的新型免疫检测方法。
利用重组CUZD1蛋白作为固相抗原，开发了两种用于检测IgG和IgA CUZD1自身抗体的免疫检测方法。分析了来自100例CrD患者、100例UC患者、129例接受各种自身免疫性疾病（vAD）评估的患者以及50名对照个体的血清样本。
开发了两种用于检测IgG和IgA CUZD1特异性抗体的免疫荧光测定法。在12.5%（25/200）的IBD患者中检测到CUZD1自身抗体，其中包括16%的CrD患者和9%的UC患者（CrD与UC相比，p<0.05），而疑似患有vAD的患者中这一比例为3.1%（4/129）（CrD与AD相比，p<0.05；UC与AD相比，p=0.08）。未发现CUZD1自身抗体阳性与疾病部位、发病年龄或疾病表型相关。
这是第一项描述新型IgA和IgG CUZD1自身抗体酶联免疫吸附测定的研究。这些免疫检测方法与标准IIF技术高度一致，可用于多中心研究，以探讨CUZD1自身抗体的诊断和临床应用。
